NASDAQ:ENTX Entera Bio Q4 2024 Earnings Report $2.81 -0.17 (-5.70%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$2.75 -0.06 (-2.14%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Entera Bio EPS ResultsActual EPS-$0.06Consensus EPS -$0.08Beat/MissBeat by +$0.02One Year Ago EPSN/AEntera Bio Revenue ResultsActual Revenue$0.04 millionExpected Revenue$0.04 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AEntera Bio Announcement DetailsQuarterQ4 2024Date3/28/2025TimeBefore Market OpensConference Call DateThursday, March 27, 2025Conference Call Time7:00PM ETUpcoming EarningsEntera Bio's Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Entera Bio Earnings HeadlinesEntera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX)September 23 at 1:36 PM | markets.businessinsider.comLeerink Partners Begins Coverage on Entera Bio (NASDAQ:ENTX)September 20, 2026 | americanbankingnews.comElon gets it. Do you?Moderna's stock jumped nearly 200% in a single day after a successful Phase 3 trial for its cancer drug, and Merck added $43 billion to its market cap on the same news. Porter & Co. says AI-driven drug discovery and automated labs are cutting development timelines by up to 80% and lifting early clinical success rates to 90%, fueling what they call biotech's Ignition Point.September 24 at 1:00 AM | Porter & Company (Ad)Leerink Partners initiates coverage of Entera Bio with outperform ratingSeptember 19, 2026 | msn.comEntera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)September 18, 2026 | markets.businessinsider.comContrasting Anika Therapeutics (NASDAQ:ANIK) & Entera Bio (NASDAQ:ENTX)September 14, 2026 | americanbankingnews.comSee More Entera Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Entera Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entera Bio and other key companies, straight to your email. Email Address About Entera BioEntera Bio (NASDAQ:ENTX) is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence. Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism. The company has also evaluated applications of its platform in other therapeutic areas. Founded in 2010 and headquartered in Jerusalem, Israel, Entera Bio conducts its development activities for international markets, including the United States. The company is led by David Amsellem, its co-founder and chief executive officer. Entera Bio’s shares trade on the Nasdaq under the symbol ENTX.View Entera Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
